Menu

FDA Approves Second CAR T-Cell Therapy

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

Oct 19, 2017
Ashley P. Taylor

ISTOCK, 7ACTIVESTUDIOThe Food and Drug Administration yesterday (October 18, 2017) approved the chimeric antigen receptor (CAR) T-cell therapy Yescarta to treat patients with certain types of large B-cell lymphomas who have relapsed or not responded to two other types of cancer treatments. It is the second CAR T-cell therapy approved in the U.S.

“Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” FDA Commissioner Scott Gottlieb says in a statement.

“There will likely be thousands of lives saved in the next few years because of it,” David Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, tells NBC News.

CAR T-cell therapies work by engineering a patient’s own immune cells to target cancer cells.

See “The CAR T-Cell Race

In August, the FDA approved a CAR T-cell therapy, Kymriah, produced by Novartis, for acute lymphoblastic leukemia. Like Yescarta, Kymriah was also approved only for patients for whom other therapies have twice failed.

Development of the treatment began at the National Cancer Institute, then moved to Kite in 2012, The New York Times reports. Gilead acquired Kite in August. The FDA granted the approval to Kite, which will continue to produce the drug. That process, which takes about 17 days, involves shipping a patient’s cells to Kite’s cell-processing facility in California where they will be engineered, then freezing the cells and shipping them back to the patient’s hospital, according to The New York Times.

Patients with large B-cell lymphoma who were treated with Yescarta had a 51 percent complete remission rate in a multicenter clinical trial, according to the FDA statement.

The treatment comes with the risk of life-threatening side effects, including “high fevers, crashing blood pressure, lung congestion and neurological problems,” The New York Times reports. It also very expensive, with a list price of $373,000, according to a Kite Pharma release.

“Yes, it can pose life threatening problems,” Tina Bureau, who took Yescarta as part of the clinical trial and whose lymphoma is in remission, tells The New York Times. “But when you’re in a situation where your life’s threatened anyway, I don’t feel you have anything to lose.”

See “Marking CAR T-Cell Therapy Safer

“Together, Gilead and Kite will accelerate studies of CAR-T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors,” David Chang, chief medical officer at Kite, tells The Times of Israel, “with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.